Donui Pharmaceutical (02348.HK) announced that Inuximab (PCSK9 monoclonal antibody) developed by the joint venture company Congrong Oriental has completed a key registered phase III clinical trial for the treatment of primary hypercholesterolemia and mixed hyperlipidemia in China ahead of schedule.
According to the company, clinical studies have shown that inuximab can more completely inhibit PCSK9 than the target products, and can significantly reduce the cholesterol of all patients given drugs. We look forward to the early approval of the products on the market, so as to provide more choices for a large number of cardiovascular patients in China.